Abstract

Helicobacter pylori (H. pylori) has so far infected more than half the global population. It is the most important and controllable risk factor for gastric cancer. The elderly, who are at a higher incidence of the infection, are also commonly found to develop antibiotic resistance. The symptoms, diagnosis, clinical features (of gastric or extra-digestive diseases), and treatment of H. pylori infection in the elderly, are different from that in the non-elderly. Health conditions, including comorbidities and combined medication have limited the use of regular therapies in elderly patients. However, they can still benefit from eradication therapy, thus preventing gastric mucosal lesions and gastric cancer. In addition, new approaches, such as dual therapy and complementary therapy, have the potential to treat older patients with H. pylori infection.

Highlights

  • Aging is an inexorable process in the human life cycle

  • H. pylori affects individuals of different age groups, the elderly have a higher prevalence of H. pylori infection, and risk of developing atrophic gastritis, and stomach cancer [6,7,8]

  • H. pylori infection is associated with the occurrence of peptic ulcers, chronic atrophic gastritis, gastric cancer etc

Read more

Summary

Frontiers in Medicine

Helicobacter pylori (H. pylori) has so far infected more than half the global population. It is the most important and controllable risk factor for gastric cancer. The symptoms, diagnosis, clinical features (of gastric or extra-digestive diseases), and treatment of H. pylori infection in the elderly, are different from that in the non-elderly. Health conditions, including comorbidities and combined medication have limited the use of regular therapies in elderly patients. They can still benefit from eradication therapy, preventing gastric mucosal lesions and gastric cancer. New approaches, such as dual therapy and complementary therapy, have the potential to treat older patients with H. pylori infection

INTRODUCTION
CHARACTERISTICS OF AGING STOMACH
Invasive Tests
CLINICAL PRESENTATION
Peptic Ulcer Disease
Chronic Atrophic Gastritis
Gastroesophageal Reflux Disease
Gastric Cancer
Constraints in Treatment
Economic Impact
Levofloxacin triple therapy Levofloxacin sequential therapy
Eradication Regimens
Findings
Potential Treatments
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.